Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review. Koeser L, McCrone P Expert Rev Pharmacoecon Outcomes Res. 2013 Apr; 13(2):171-82. PMID: 23570427. Abstract CommentRecommendBookmarkWatch